Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.